BR112017021083A2 - piridopirimidinonas e seu uso como moduladores do receptor de nmda - Google Patents

piridopirimidinonas e seu uso como moduladores do receptor de nmda

Info

Publication number
BR112017021083A2
BR112017021083A2 BR112017021083-5A BR112017021083A BR112017021083A2 BR 112017021083 A2 BR112017021083 A2 BR 112017021083A2 BR 112017021083 A BR112017021083 A BR 112017021083A BR 112017021083 A2 BR112017021083 A2 BR 112017021083A2
Authority
BR
Brazil
Prior art keywords
nmda receptor
receptor modulators
pyridopyrimidinones
compounds
neurological
Prior art date
Application number
BR112017021083-5A
Other languages
English (en)
Inventor
Volgraf Matthew
Jiang Yu
Villemure Elisia
sellers Benjamin
Wu Guosheng
Lu Aijun
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112017021083A2 publication Critical patent/BR112017021083A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

a invenção refere-se a compostos de piridopirimidinona da fórmula i ou sais farmaceuticamente aceitáveis dos mesmos, em que x, r1, r2, r3, r4, r5 e r6 são como definidos aqui, como também composições farmacêuticas que compreendem tais compostos, úteis como moduladores do receptor de nmda no tratamento de condições neurológicas e psiquiátricas.
BR112017021083-5A 2015-04-15 2016-04-12 piridopirimidinonas e seu uso como moduladores do receptor de nmda BR112017021083A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/076617 2015-04-15
CN2015076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Publications (1)

Publication Number Publication Date
BR112017021083A2 true BR112017021083A2 (pt) 2018-07-03

Family

ID=55809078

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021083-5A BR112017021083A2 (pt) 2015-04-15 2016-04-12 piridopirimidinonas e seu uso como moduladores do receptor de nmda

Country Status (20)

Country Link
US (1) US10280165B2 (pt)
EP (1) EP3283487B1 (pt)
JP (2) JP6847851B2 (pt)
KR (1) KR20170137137A (pt)
CN (1) CN107531696B (pt)
AU (1) AU2016248886B2 (pt)
BR (1) BR112017021083A2 (pt)
CA (1) CA2982217A1 (pt)
CL (1) CL2017002498A1 (pt)
CO (1) CO2017009989A2 (pt)
CR (1) CR20170462A (pt)
HK (1) HK1245259A1 (pt)
IL (1) IL254921B (pt)
MX (1) MX2017013101A (pt)
PE (1) PE20180316A1 (pt)
PH (1) PH12017501876A1 (pt)
RU (1) RU2717665C2 (pt)
SG (1) SG11201708294YA (pt)
UA (1) UA120647C2 (pt)
WO (1) WO2016166078A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2690355T3 (es) 2013-10-11 2018-11-20 F. Hoffmann-La Roche Ag Tiazolopirimidinonas como moduladores de la actividad del receptor de NMDA
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AU2004249730A1 (en) * 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
CA2915536C (en) * 2013-06-19 2021-10-19 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives
ES2690355T3 (es) 2013-10-11 2018-11-20 F. Hoffmann-La Roche Ag Tiazolopirimidinonas como moduladores de la actividad del receptor de NMDA
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators

Also Published As

Publication number Publication date
PE20180316A1 (es) 2018-02-09
AU2016248886B2 (en) 2020-09-10
JP2021046428A (ja) 2021-03-25
IL254921B (en) 2021-02-28
IL254921A0 (en) 2017-12-31
EP3283487B1 (en) 2019-10-16
RU2017139254A (ru) 2019-05-15
CO2017009989A2 (es) 2018-01-05
EP3283487A1 (en) 2018-02-21
CA2982217A1 (en) 2016-10-20
CR20170462A (es) 2018-02-01
US20180127414A1 (en) 2018-05-10
AU2016248886A1 (en) 2017-10-12
US10280165B2 (en) 2019-05-07
SG11201708294YA (en) 2017-11-29
PH12017501876A1 (en) 2018-02-26
MX2017013101A (es) 2018-01-30
HK1245259A1 (zh) 2018-08-24
JP2018511627A (ja) 2018-04-26
RU2017139254A3 (pt) 2019-09-30
CN107531696A (zh) 2018-01-02
KR20170137137A (ko) 2017-12-12
CN107531696B (zh) 2021-03-16
JP6847851B2 (ja) 2021-03-24
RU2717665C2 (ru) 2020-03-24
WO2016166078A1 (en) 2016-10-20
CL2017002498A1 (es) 2018-04-20
UA120647C2 (uk) 2020-01-10

Similar Documents

Publication Publication Date Title
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
PH12016501813B1 (en) 1,3-benzodioxole derivative
BR112018009281A8 (pt) composições para tratar atrofia muscular espinhal
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MD3313817T2 (ro) Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016011016A8 (pt) derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112016022046A8 (pt) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
PH12015502632A1 (en) Cxcr7 receptor modulators
BR112017021083A2 (pt) piridopirimidinonas e seu uso como moduladores do receptor de nmda
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
BR112019001407A2 (pt) compostos e composições e usos dos mesmos
BR112019000290A2 (pt) pró-fármacos de fósforo dos estimuladores da scg
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2718 DE 07-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.